Stock AnalizArrowhead Pharmaceuticals, Inc. ARWR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) is a healthcare company listed in the US with a market value of about $6.8B. In fiscal year 2026 it had revenue of $451M and net income of -$724M, a net margin of -160.6%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 27% a year, a 5-year average ROIC of -45%.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $451M | $829M | $4M | $241M | $243M | $138M | $88M | $169M | $16M | $31M |
| Net income | -$724M | -$2M | -$599M | -$205M | -$176M | -$141M | -$85M | $68M | -$54M | -$34M |
| Free cash flow | -$284M | $157M | -$604M | -$331M | -$189M | $148M | -$108M | $161M | -$49M | -$32M |
| EPS (diluted) | $-5.11 | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.69 | $-0.65 | $-0.47 |
| Net margin | -160.6% | -0.2% | -16882.4% | -85.3% | -72.4% | -101.8% | -96.1% | 40.3% | -337.3% | -109.5% |
| ROIC | -78.3% | 9.3% | -86.0% | -41.9% | -29.4% | -27.1% | -15.2% | 24.9% | -45.0% | -34.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $106.07, 122% above the current price; targets range from $73.00 to $126.00; the consensus rating is “Strong buy”; expected EPS is $-5.52 for the fiscal year ending September 30, 2027.
Frequently asked questions
Does Arrowhead Pharmaceuticals pay a dividend?
Not currently.
Is Arrowhead Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Arrowhead Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.